Senzime (SEZI) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
18 Feb, 2026Executive summary
Achieved over 90% revenue growth in constant currencies for 2025, reaching 111.4 MSEK in sales, with strong Q4 momentum and major wins in the US, Europe, and Asia.
Transitioned to a sensor-driven business, with sensors now over 70% of sales and recurring sales of disposable sensors increasing to over 440,000 units in 2025.
Launched next-generation TetraGraph system and EMGINE software suite, driving higher adoption and workflow improvements.
Underlying gross margin improved to 66.7% for the year, despite negative impacts from US tariffs, currency effects, and a one-time SEK 10.7 million inventory write-down.
Adjusted EBITDA improved by 16% year-over-year, with a clear path toward profitability and positive cash flow targeted for Q4 2026.
Financial highlights
Full-year reported revenues grew to 111.4 MSEK, with Q4 revenues up 125% in constant currencies to 31.2 MSEK.
Q4 underlying gross margin reached 69.3%, and full-year margin was 66.7%.
Adjusted EBITDA for 2025 improved to SEK -88,374k from -105,507k in 2024, a 16% improvement.
Operating expenses increased only 1.9% year-over-year despite significant commercial investments.
Ended the year with SEK 74 million in cash.
Outlook and guidance
Targeting continued strong sales growth and positive cash flow by Q4 2026.
Expecting further gross margin improvements through price increases and new business models.
Long-term ambition to exceed SEK 1 billion in revenues by 2030.
Focus for 2026 is on maintaining strong sales growth, fixed expenses, and further gross margin improvement.
Latest events from Senzime
- Q2 sales up 76% to SEK 14.9m, driven by US growth and major new hospital contracts.SEZI
Q2 202423 Jan 2026 - Q3 sales up 90% year-over-year, driven by sensor demand and US and Asia growth.SEZI
Q3 202416 Jan 2026 - 2024 sales up 65%, next-gen TetraGraph launched, 2025 revenue set to double.SEZI
Q4 202424 Dec 2025 - 80% revenue growth, improved EBITDA, and major U.S. contracts drive strong expansion.SEZI
Q3 202510 Dec 2025 - Net sales up 94% to SEK 23.5m, with record global growth and improved gross margin.SEZI
Q1 202528 Nov 2025 - Advanced nerve monitoring is revolutionizing anesthesia safety and driving rapid global growth.SEZI
Life Science Summit 202519 Nov 2025 - 90% sales growth, robust US momentum, and SEK 110.4M raised for expansion.SEZI
Q2 202516 Nov 2025 - Electromyography-based monitoring is rapidly becoming the new standard, driving hyper-growth and global expansion.SEZI
European Growth Conference 202512 Sep 2025